Skip to main content

Table 3 Median values of FMD and NMD

From: Effect of ivabradine-induced heart rate reduction on flow-mediated dilation measured with high-sensitivity ultrasound in patients with stable coronary heart disease

  Baseline Acute effect Sustained effect
  8.00 a.m. 12.00 a.m. 8.00 a.m. 12.00 a.m. 8.00 a.m.
FMDbase (mm) 3.8 [3.3-4.2] 3.8 [3.4-4.2] 3.7 [3.3-4.2] 3.6 [3.3-4.1] 3.6 [3.4-4.3]
FMDmax(mm) 3.9 [3.5-4.3] 4.0 [3.6-4.3] 3.8 [3.5-4.3] 3.9 [3.5-4.3] 3.8 [3.6-4.4]
FMDmax (%) 4.8 [2.4-6.5] 5.3 [2.2-7.5] 5.0 [2.4-7.9] 4.9 [2.7-9.8] 6.1 [4.3-8.2]
NMDbase (mm) 3.6 [3.2-4.2] 4.1 [3.4-4.2] 3.8 [3.1-4.4] 4.1 [3.3-4.4] 3.7 [3.3-4.2]
NMDmax (mm) 4.4 [4.1-4.8] 4.4 [4.2-4.9] 4.4 [3.9-5.0] 4.4 [4.1-5.1] 4.4 [4.1-4.9]
NMDmax (%) 19.1 [13.2-25.7] 17.0 [12.5-23.7] 16.7 [13.0-24.6] 17.3 [9.8-23.7] 21.1 [13.5-29.6]
  1. Values are presented as median values (Q1 – Q3). FMDbase: diameter of brachial artery before hyperaemic stimulus; FMDmax : maximum dilation of brachial artery after hyperaemic stimulus, shown in mm as maximum percentage change in brachial artery diameter compared with FMDbase; NMDbase: diameter of brachial artery before application of 0.4 mg nitroglycerine; NMDmax: maximum dilation of brachial artery after application of 0.4 mg nitroglycerine, shown in mm and as maximum percentage change in brachial artery diameter compared with FMDbase.. Baseline: FMD at 08.00 and 12.00 at study visit 1 (without ivabradine); Acute effect: FMD before and 4 hours after first intake of 7,5 mg ivabradine; Sustained effect: FMD after 4 weeks of ivabradine intake twice daily (10 to 15 mg).